Course and treatment of severe osteoporosis complicated by calciphylaxis: a case report.

Calciphylaxis, also known as calcific uremic arteriolopathy (CUA), is a rare disorder with many unknown treatment and diagnostic aspects. It is characterized by calcification and thrombosis of small blood vessels. This disease leads to progressive skin calcification, necrotizing ulcers, and infections and is associated with a high mortality rate.

Calcific Uremic Arteriolopathy (CUA) Among Malaysian Dialysis Patients: Clinical Characteristics, Treatment, and Outcomes.

Background Calcific uremic arteriolopathy (CUA) is a rare but debilitating disease affecting patients with kidney disease. Reported risk factors of CUA in the literature include female sex, obesity, diabetes mellitus, and vitamin K antagonists' (VKAs) usage. CUA prevalence in Malaysia is unknown and has not been reported before.

Anticoagulant-associated calciphylaxis: analysis of USFDA adverse event report system and clinical feature analysis of reported cases.

Background: Calciphylaxis is a serious, potentially fatal condition resulting in pathological calcification of soft tissues. While associated with chronic kidney disease, data regarding anticoagulant involvement remain limited.

Research Design And Methods: The United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) database was searched to identify calciphylaxis reports linked to anticoagulants from 2004 to 2024.

Calciphylaxis in a Patient on Hemodialysis: A Case Report.

Calciphylaxis is a rare but life-threatening complication of end-stage renal disease (ESRD), most often seen in patients undergoing hemodialysis. This condition is driven by calcium deposition in small blood vessels, leading to restricted blood flow, tissue ischemia, and often severe pain. While calciphylaxis typically affects areas with increased adiposity, such as the abdomen and proximal extremities, it can manifest on any skin surface, including rare sites like the genital region.

Hyperbaric oxygen therapy enables pain reduction and healing in painful chronic wounds, including in calciphylaxis.

Background: The effects of hyperbaric oxygen therapy (HBOT) on wound healing have been demonstrated mainly in diabetic foot ulcer.

Objectives: To study the efficacy and safety of HBOT in chronic painful wounds, excluding diabetic foot ulcers.

Methods: From 2008 to 2021, patients with chronic wounds showing no clinical improvement for more than 1 month, who were in pain despite the use of level 2 or 3 analgesics, and who had undergone HBOT sessions, were included in a monocentric retrospective study.

Redefining Calciphylaxis as a Uniquely Bone Forming Subcutaneous C5b-9-Mediated Microvascular Injury Syndrome Associated With Localized Subcutaneous and Systemic Complement Pathway Activation.

Background: Microvascular thrombosis is key to the pathogenesis of calciphylaxis. C5b-9-mediated microvascular injury reflective of complement pathway activation could be a key pathophysiologic event.

Methods: We conducted a retrospective multicenter study of 24 patients who have had biopsy-supported calciphylaxis from the 2010-2022 data base from Emory where C5b-9 immunohistochemistry (IHC) had not been conducted and the 2019-2023 data base from Cornell where C5b-9 IHC was done as part of the routine calciphylaxis work up.

Hyperbaric oxygen treatment in addition to conventional multidisciplinary care in patients with calciphylaxis.

Background: Calciphylaxis is a rare and serious complication in patients with kidney disease. It has few treatment options and poor prognosis. Hyperbaric oxygen therapy (HBOT) may improve wound healing and was added to our conventional care in 2012.

Gastrointestinal calciphylaxis: a rare and devastating complication in end-stage kidney disease.

Calciphylaxis, also known as calcific uremic arteriolopathy, is a rare and severe condition that predominantly affects individuals with end-stage kidney disease (ESKD). It manifests through vascular calcifications that precipitate tissue necrosis, with cutaneous manifestations being common. However, gastrointestinal involvement is an infrequent but gravely serious occurrence.

A case of rapidly progressive unilateral non-nephrogenic hemorrhagic bullous calciphylaxis responding to systemic sodium thiosulfate therapy.

Background: Calciphylaxis is a rare and life-threatening condition characterized by cutaneous necrosis resulting from vessel calcification and thrombosis. Commonly associated with end-stage renal disease and hyperparathyroidism, calciphylaxis presents as retiform purpura evolving into necrotic eschars.

Case Report: This report details an atypical case of non-nephrogenic unilateral bullous calciphylaxis in a 71-year-old female, emphasizing the importance of considering calciphylaxis in the differential diagnosis of bullous disorders.

Penile Calciphylaxis: A Rare-Case Report of Calcific Uremic Arteriolopathy in a Patient with End-Stage Renal Disease and Severe Vascular Insufficiency.

Penile calciphylaxis is a rare and life-threatening condition, most commonly seen in patients with end-stage renal disease (ESRD) undergoing dialysis. The pathophysiology includes calcification of small blood vessels, leading to ischemic changes, most commonly affecting the extremities. Treatment modalities vary based on the history and condition of the patient.